ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

TY - JOUR

T1 - ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

AU - ESMO Guidelines Committee

AU - Powles, T.

AU - Albiges, L.

AU - Bex, A.

AU - Grünwald, V.

AU - Porta, C.

AU - Procopio, G.

AU - Schmidinger, M.

AU - Suárez, C.

AU - de Velasco, G.

N1 - Funding Information: The ESMO Guidelines Committee acknowledges and thanks the following people who have acted as reviewers for this article: Ignacio Duran Martinez, Ravindran Kanesvaran and Bernadett Szabados, ESMO Faculty (genitourinary tumours, non-prostate). Manuscript editing support was provided by Louise Green, Catherine Evans and Jennifer Lamarre (ESMO Guidelines staff). Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urani Dafni ESMO-MCBS Working Group Member/Frontier Science Foundation Hellas and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino (ESMO Scientific Affairs staff) and Angela Corstorphine of Kstorfin Medical Communications Ltd provided coordination and support of the ESMO-MCBS scores and preparation of the ESMO-MCBS table. No external funding has been received for the preparation of this article. Production costs have been covered by ESMO from central funds. TP reports research funding from Merck Serono, Merck Sharp & Dohme (MSD), Roche, Bristol Myers Squibb (BMS), AstraZeneca, Astellas, Novartis, Johnson and Johnson, Seattle Genetics, Pfizer, Exelixis and Eisai and honoraria from Merck Serono, MSD, Roche, BMS, AstraZeneca, Astellas, Novartis, Johnson and Johnson, Seattle Genetics, Pfizer, Exelixis and Eisai; LA reports research funding from BMS (Institution) and advisory roles (Institution) for Astellas, AstraZeneca, BMS, Corvus Pharmaceuticals, Ipsen, Janssen, Merck & Co, MSD, Novartis, Pfizer and Eisai; AB has reported restricted educational grant for an investigator-initiated trial of neoadjuvant therapy in high-risk renal cancer from Pfizer, steering committee member and local investigator in an adjuvant trial for BMS, steering committee member and principal investigator in an adjuvant trial for Roche/Genentech, medical steering committee member to advise the patient advocacy group on medical topics and strategy for the International Kidney Cancer Coalition and medical steering committee member to advise the patient advocacy group on medical topics and strategy for the Kidney Cancer Association; VG has reported advisory roles for BMS, MSD, EISAI, EUSA Pharma, Merck-Serono, Nanobiotix, Pfizer and Roche, speaker's honoraria for AstraZeneca, BMS, MSD, EISAI, Ipsen, Janssen-Cilag, Merck-Serono, Pfizer and Roche, stocks in AstraZeneca, BMS, MSD and Seattle Genetics, steering committee member for BMS, EISAI, Ipsen, Novartis and PharmaMar and research grants from AstraZeneca, BMS, MSD, Ipsen and Pfizer; CP reports consultant/speaker honoraria from Angelini Pharma, AstraZeneca, BMS, Eisai, EUSA Pharma, General Electric, Ipsen, Janssen, Merck, MSD, Novartis and Pfizer, expert testimony for EUSA Pharma and Pfizer and travel support from Roche and Protocol Steering Committee member for BMS, Eisai and EUSA Pharma; GP reports honoraria for advisory board/consultant/speaker from AstraZeneca, Bayer, BMS, Eisai, Janssen, Ipsen, Merck, MSD, Novartis and Pfizer and research grants from Ipsen and Novartis; MS reports consultant/speaker honoraria from Pfizer, BMS, Merck, MSD, EISAI, EUSA Pharma, Ipsen and Alkermes, travel support from Pfizer and Roche and Protocol Steering Committee member for Pfizer and Merck; CSR reports honoraria for advisory board for Astellas Pharma, Bayer, BMS, EUSA Pharma, Ipsen, Novartis, Pfizer, Sanofi-Aventis, MSD and Hoffman-La Roche Ltd and speaker fees for Astellas, BMS, Ipsen, Pfizer and Hoffman-La Roche and research grant from Ipsen; GdV reports advisory boards for Astellas, Bayer, BMS, EUSA Pharma, Ipsen, MSD, Pfizer and Merck, invited speaker for Astellas, BMS, Ipsen, MSD, Pfizer, Roche and Merck and institutional research grant from Roche.

PY - 2021/12/1

Y1 - 2021/12/1

KW - PD-1 inhibitor therapy

KW - VEGFR TKI

KW - ccRCC

KW - papillary RCC

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85118490545&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.09.014

DO - 10.1016/j.annonc.2021.09.014

M3 - Article

C2 - 34597799

AN - SCOPUS:85118490545

SN - 0923-7534

VL - 32

SP - 1511

EP - 1519

JO - Annals of Oncology

JF - Annals of Oncology

IS - 12

ER -